Trials / Unknown
UnknownNCT04392726
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- —
Summary
The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims: 1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping. 2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.
Conditions
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
- First posted
- 2020-05-19
- Last updated
- 2022-05-10
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04392726. Inclusion in this directory is not an endorsement.